We are a biotechnology company with a mission to profoundly improve treatment options for patients with retinal vascular disease.
Our lead asset, EXN407 is poised to become the first topical therapy for diseases such as diabetic retinopathy and diabetic macular oedema and is set to enter Phase IIb clinical trials in 2024.